Spotlight on HDL-raising therapies: insights from the torcetrapib trials
- 22 April 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Cardiovascular Medicine
- Vol. 5 (6) , 329-336
- https://doi.org/10.1038/ncpcardio1191
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- High-Density Lipoprotein Mimetics: Focus on Synthetic High-Density LipoproteinThe American Journal of Cardiology, 2007
- Nicotinic Acid (Niacin) Receptor Agonists: Will They Be Useful Therapeutic Agents?The American Journal of Cardiology, 2007
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Illuminating HDL — Is It Still a Viable Therapeutic Target?New England Journal of Medicine, 2007
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007
- Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDLJournal of Clinical Investigation, 2007
- New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol TransportCirculation Research, 2005
- Elevated Triglyceride Content Diminishes the Capacity of High Density Lipoprotein to Deliver Cholesteryl Esters via the Scavenger Receptor Class B Type I (SR-BI)Published by Elsevier ,2001
- Atherogenesis: a postprandial phenomenon.Circulation, 1979